These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28398426)

  • 1. Reversible cutaneous side effects of vismodegib treatment.
    Kwong B; Danial C; Liu A; Chun KA; Chang AL
    Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract]   [Full Text] [Related]  

  • 3. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent alopecia induced by vismodegib.
    Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
    Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
    [No Abstract]   [Full Text] [Related]  

  • 5. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 6. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
    Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
    JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
    [No Abstract]   [Full Text] [Related]  

  • 7. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 8. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report of cutaneous side effects of vismodegib treatment.
    Caplash G; Curragh DS; Halliday L; Huilgol SC; Selva D
    Clin Exp Ophthalmol; 2020 Jan; 48(1):123-125. PubMed ID: 31569297
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
    Kutiel TS; Vornicova O; Bar-Sela G
    J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
    Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
    Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
    Orouji A; Goerdt S; Utikal J; Leverkus M
    Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
    [No Abstract]   [Full Text] [Related]  

  • 16. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients.
    Girard E; Lacour A; Abi Rached H; Ramdane N; Templier C; Dziwniel V; Desmedt E; Le Rhun E; Mortier L
    J Am Acad Dermatol; 2018 Jun; 78(6):1213-1216.e2. PubMed ID: 29203435
    [No Abstract]   [Full Text] [Related]  

  • 18. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
    Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
    Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
    Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
    Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
    J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.